Form 4: Merus Director Cashes Out Options in Genmab Tender Offer
Statement of Changes in Beneficial Ownership
Merus N.V. director Anand Mehra disposed of all share options following Genmab's tender offer at $97.00 per share.
Summary
- Merus N.V. director Anand Mehra reported changes in beneficial ownership due to a tender offer.
- Genmab A/S, through its subsidiary Genmab Holding II B.V., commenced a tender offer for all outstanding common shares of Merus N.V.
- The tender offer was initiated following a Transaction Agreement entered into on September 29, 2025.
- On December 12, 2025, the Purchaser accepted all validly tendered shares at an Offer Consideration of $97.00 per share in cash.
- All of Anand Mehra's share options were cancelled as part of the Transaction Agreement.
- Option holders received a cash payment equal to the product of (i) the Offer Consideration minus the option's exercise price and (ii) the number of shares underlying the option.
Sentiment
Score: 8
Explanation: The filing reports the successful completion of a tender offer at a premium price, resulting in a cash payout for shareholders and option holders, which is a positive outcome for those involved.
Positives
- Shareholders who tendered received a cash payment of $97.00 per share, indicating a premium.
- Director Anand Mehra's share options were converted into cash, providing liquidity and value realization.
Negatives
- No explicit negatives are detailed in this filing, which reports a completed transaction.
Future Outlook
The filing reports a completed transaction and does not provide forward-looking statements or guidance.
Stakeholder Impact
- Shareholders who tendered their shares received a cash payment of $97.00 per share.
- Option holders, including director Anand Mehra, received a cash payment for their cancelled options, based on the difference between the offer price and the exercise price.
Next Steps
- Payment of the Offer Consideration to tendering shareholders and cash payment for cancelled options will occur as soon as practicable following the Acceptance Time.
Key Dates
| Date | Description |
|---|---|
| 09/29/2025 | Merus N.V. entered into a transaction agreement with Genmab A/S and Genmab Holding II B.V. |
| 12/12/2025 | Purchaser accepted all validly tendered shares in the tender offer (Acceptance Time), and director's share options were cancelled. |
Keywords
Merus N.V., MRUS, Genmab, tender offer, share options, beneficial ownership, acquisition, insider transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.